Purpose of review Spontaneous lymphoma in pet dogs is increasingly recognized as an ideal model for studying the disease in humans and for developing new targeted therapeutics for patients. Increasing interest by funding agencies, the private sector, and multidisciplinary academic collaborations between different disciplines and sectors now enables large knowledge gaps to be addressed and provides additional proof-of-concept examples to showcase the significance of the canine model.
INTRODUCTION
Naturally occurring cancer in pet dogs has in recent years garnered the attention of researchers as a potentially representative and predictive model for human cancer. Canine lymphoma in particular shares many of the characteristics of non-Hodgkin lymphoma in people, having a similar clinical presentation, molecular and immunophenotypic composition, diagnostic and therapeutic protocols, and treatment response (Fig. 1) . Spontaneous lymphoma in dogs is now being advocated as the link between mouse models and human clinical trials in testing new lymphoma therapies, with the potential to alleviate some of the bottlenecks in the traditional drug-development pipeline (Fig. 2) . In the past year, growing efforts have been made to advance the canine model through investigations of the applicability of diagnostic and prognostic human biomarkers to dogs with lymphoma, expansion of canine genomic, proteomic, and other -omic data, and developing additional canine lymphoid cell-line resources. This past year has also seen an expansion of immunotherapy research and the preclinical testing of novel targeted agents in canine cells and patients, highlighting the particularly exciting opportunities of the canine model for
RATIONALE FOR A CANINE MODEL OF LYMPHOMA
Currently, it takes 16 years for a new drug to come to market at a $2 billion cost, and only 1 out of 10 000 compounds become U.S. Food and Drug Administration (FDA) approved [1] . Even among those oncology drugs that are effective in mice, only 11% are eventually approved for use in humans [2] . A significant cause of this high failure rate is likely the reliance on rodents as preclinical models, when they frequently do not reflect the tumor biology and pathophysiology occurring in human patients [3] . Mouse models used in drug development have compromised immune systems, decreased genetic heterogeneity, and rarely develop naturally occurring lymphoma [4] . These mice lack complex genetic and gene-environment effects, and their immunoincompetence ignores a central mechanism of cancer risk and development. In contrast, pet dogs naturally develop lymphoma at a higher incidence rate than humans (13-114 per 100 000 individuals compared with 20 per 100 000 in humans) [5] and have clinical presentations and diagnostic features comparable to that in people [6] . Diffuse large B-cell lymphoma (DLBCL) is the most common subtype in humans and dogs, accounting for $70% of canine B-cell lymphomas [5] . Dogs are also more genetically similar to humans, have increased genetic variation and intact immune systems, and are exposed to the same environmental risk factors as their owners, perhaps being able to serve as sentinels for these environmental hazards [4, 7] . State-of-the-art veterinary care is readily available and pet owners are usually eager to enroll dogs in clinical trials and maintain high compliance due to limited availability of therapies and expense of therapy off-study [2] . Minimally invasive procedures can be routinely carried out and as dogs typically present with palpable lymphadenopathy, serial biopsies are feasible (Fig. 3) [8] . Although dogs require larger drug doses compared with mice, which incurs higher costs, they model the pharmacokinetic and toxicity properties of a new drug more readily. The shorter lifespan of dogs and the faster progression of lymphoma in this species in comparison to humans enable timely assessments of novel cancer treatments [4] and enable chemoprevention studies. By using a spontaneous canine lymphoma model, the time and
KEY POINTS
The use of a spontaneous canine lymphoma model in drug development can improve the predictability of preclinical trials and reduce the time and costs required for drugs to come to market.
The concept of canine lymphoma serving as a useful model for the human form of the disease is becoming more mainstream with the development of necessary infrastructure and increased availability of funding opportunities.
Researchers this past year have sought to fill in the knowledge gaps still remaining and have provided proof-of-concept examples of the utility of the canine lymphoma model in the development of immunotherapies and other targeted therapeutics. cost required for a therapeutic target to be translated into clinical benefit can be reduced, whereas the predictability of preclinical models can be increased.
A sign that the canine lymphoma model is becoming more mainstream has been the development of much needed clinical trial infrastructure over the last decade. National organizations, such as the Veterinary Cancer Society, CTSA One Health Alliance, and the Veterinary Cooperative Oncology Group, bring together expertise for the development and standardization of clinical trials. The Comparative Oncology Program of the National Cancer Institute has established a Comparative Oncology Trials Consortium to guide rigorously controlled preclinical trials of new therapies intended for human patients [4] . A national canine cancer biospecimen repository by the Canine Comparative Oncology and Genomics Consortium was established in 2007 as a forum for sharing resources and has distributed high-quality samples to dozens of researchers (Mazcko, personal communication). In 2015, a workshop hosted by the US National Academy of Medicine (formerly the Institute of Medicine) brought veterinarians, physicians, researchers, pharmaceutical representatives, granting agencies, and government regulators together to discuss how oncology trials in dogs can better contribute to human health [8, 9 && ]. The workshop sparked new collaborations and addressed a major roadblockthe concern that a drug that shows unexpected toxicity or lack of efficacy in the dog might Studying lymphoma in a spontaneous canine model Villarnovo et al.
negatively affect its approval for use in humans. Reassurances by FDA officials will hopefully alleviate pharmaceutical concerns, as will more successfully completed trials that augment, rather than hinder, human therapeutic development. The American Veterinary Medical Association also launched a database of all open clinical trials in veterinary species this past year (ebusiness.avma.org/aahsd/study_search.aspx) as a resource for researchers recruiting patients in clinical studies and for veterinarians and pet owners searching for treatment options. This database is similar to that available for human clinical trials (ClinicalTrials.gov) and intends to include studies occurring worldwide. Funding agencies are now starting to take notice of the potential of canine cancer models. Until recently, researchers using a spontaneous canine lymphoma model have depended on funding from their own institutions or from nonprofit, animalhealth-focused foundations such as the Morris Animal Foundation and the American Kennel Club Canine Health Foundation. Historically, the National Institutes of Health (NIH) has provided limited funding for animal cancer models that haven't been developed as thoroughly as rodent models [1] . This appears to be changing, however, as the NIH in April 2016 announced funding for collaborations between veterinarians, physicians, and scientists to arrive at a better understanding of the molecular mechanisms of cancer in dogs [1] . At the time of preparation of this article, there were two open Requests for Application aiming to fund canine immunotherapy studies and trials [10] . Dogs make ideal models for developing immunotherapies as they have intact immune systems that have been antigenically challenged, in contrast to mouse models. Other traditionally human-focused cancer funding foundations such as the American Cancer Society and the Leukemia and Lymphoma Society are also now considering grants that include the canine cancer model for funding (Richards, McCleary-Wheeler, personal experience). As few dogs are cured with current chemotherapy regimens, dogs offer an opportunity to bring new treatments to the frontline treatment setting, using novel agents not just in relapsed cases, which can be the most challenging to treat. They are the only species in which one can use a 'species in kind' approach in which clinical trials can be conducted with the knowledge of pharmacokinetics and toxicities evaluated in research animals of the same species [4] . Given its breed structure and increasingly well defined genetics [11 & ], the canine lymphoma model is also well suited for developing precision medicine approaches in which clinical and molecular data from the patient are analyzed to tailor treatment targeting different pathways specifically for that individual [3] .
RECENT MOLECULAR ADVANCES
Researchers have attempted to fill in the knowledge gaps in comparative oncology and to develop the reagents and tools necessary for expanding the use of the canine lymphoma model. Here, we focus on a select group of notable studies from this past year.
APPLYING HUMAN FINDINGS TO CANINE LYMPHOMA
Various proteins that have been previously identified as potential prognostic biomarkers for human lymphoma are now being studied in dogs. Two of the most important biomarkers in human DLBCL are BCL2 and MYC, with double expressors accounting for $35% of all DLBCL patients [12] . This double-expressor lymphoma subset has a significantly worse outcome and is being targeted therapeutically in ongoing clinical trials, as these patients are often not cured by standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. When canine DLBCL was assessed for BCL2 and MYC, all patients were found to have high expression of both proteins using human scoring cutoffs [13] . When these samples were separated into 'high' and 'low' groups, as defined by expression above or below the median within the group, there was no association with clinical outcome. Therefore, combined BCL2 and MYC expression appears to be uniformly high in canine lymphoma and not prognostic of outcome.
The expression of CD25, the alpha subunit of the IL-2 receptor, has been previously reported in various subtypes of human lymphoid tumors, and CD25 positivity was associated with a poorer prognosis [14] . Mizutani et al. [15 & ] evaluated CD25 expression in canine lymphomas using immunohistochemistry (IHC) and flow cytometry and found, similar to the human work, that CD25 expression was higher in dogs with high-grade B-cell lymphoma or T-zone lymphoma than in healthy dogs. Progression-free survival was also significantly shorter in the CD25 high-expressing group, indicating CD25 could be a useful prognostic marker in both species.
Ki67 is a proliferation-associated nuclear protein expressed during the active phases of the cell cycle [16] . The prognostic significance of this protein has been contradictory in humans. Poggi et al. conducted a study evaluating 40 dogs with high-grade B-cell lymphoma with flow cytometry. They found that those dogs with intermediate levels had longer survival times and relapse-free intervals than those with low or high levels [16] . Similar findings had been previously seen in a human study [17] .
Despite the remarkable histomorphologic similarity between dogs and humans in many of the subtypes of lymphoma, Thomas et al. [18 & ] showed that at least in follicular lymphoma, the second most common subtype in human lymphoma which is much rarer in dogs, the molecular pathogenesis may not be the same. In humans, the constitutive expression of the antiapoptotic bcl2 protein is induced in most cases by a chromosomal translocation. Evaluation of 10 canine follicular lymphomas with IHC and genomic analysis found that although there was marked heterogeneity in the bcl2 protein expression as seen in humans, none had the hallmark translocation of human follicular lymphoma [18 & ]. Genomic copy number aberrations were also infrequent. The authors suggested that there may be alternative molecular mechanisms other than BCL2 translocation involved in the pathogenesis of follicular lymphoma. This illustrates how comparative oncology differences can contribute to a more comprehensive understanding of the underlying disease processes.
IMPROVING DIAGNOSTIC AND MINIMAL RESIDUAL DISEASE DETECTION METHODOLOGIES
There have been efforts to advance the methodologies available for the detection of canine lymphoma (Fig. 4) . Flow cytometry was analytically and diagnostically validated for quantifying canine large B cells in peripheral blood and bone marrow [19 & ]. As the degree of bone marrow infiltration has been shown to have prognostic significance in dogs with large B-cell lymphoma [20] , this study validates the use of flow cytometry for this purpose. Minimal residual disease is becoming an increasingly important predictive feature being incorporated into human lymphoma treatment strategies. To further improve the sensitivity of detecting residual populations of canine tumor cells after clinical remission, real-time quantitative PCR was employed by designing primers and probes based on neoplastic clones from each individual canine patient [21 && ]. As in humans, this technique was found to be a useful prognostic indicator, a marker of treatment efficacy, and a predictor of relapse for dogs with lymphoma.
EXPANSION OF GENOMIC AND PROTEOMIC DATA
In human medicine, gene-expression profiling has led to the identification of two molecularly distinct forms of DLBCL with prognostic significance. Patients with germinal center B-cell (GCB) DLBCL express genes characteristic of germinal center B cells and have a significantly better overall survival than those with activated B-cell (ABC) DLBCL which express genes normally induced during activation of peripheral B cells [22] . Although the human ABC/ GCB signature genes do not separate canine lymphomas as cleanly, they have been used to generate a 'canine-specific' ABC/GCB DLBCL signature that separates canine DLBCL into two prognostically distinct groups, mirroring human DLBCL [23] . The ABC/GCB differentiating genes, although different from those in human DLBCL, are nonetheless involved in the same pathways and processes as the human genes. For instance, increased expression of NF-kB pathway genes has been found in canine DLBCL [24] and associated with poor prognosis [23] and inactivating mutations of the negative NF-kB regulator TRAF3 [25] have been found. Whether this ABC/GCB grouping based on gene expression truly reflects two distinct cell types of origin in canine lymphoma is still unclear and the subject of ongoing research.
The lack of genomic annotations and lack of reagents for mining veterinary genomes, proteomes, and metabolomes have been signaled out as the most significant gaps in comparative oncology Studying lymphoma in a spontaneous canine model Villarnovo et al. [3, 8] . In an effort to make progress on this front, the largest canine genome-wide association study to date found a significant association for developing lymphoma near the MCC, MXD3, and FGFR4 genes in Golden Retrievers [11 & ] . The authors' model estimates that a much smaller number of cases and controls are needed than typically used in human studies to yield significant genetic associations, and this was borne out as the lymphoma locus achieved genome-wide significance with only 34 cases and 48 controls. This makes the dog an appealing model for studying and mapping complex phenotypes like cancer predisposition, as well as comparing the contributions of germ-line versus somatic mutations in cancer genomes. Previous exomesequencing studies in canine lymphoma have found recurrent somatic mutations in TRAF3 (20-35% of cases), FBXW7 (25%), POT1 (17%), and TP53 (16%) [26] . These genes have also been found to be recurrently mutated in human DLBCL (TRAF3, TP53) or other lymphoid malignancies (FBXW7, POT1) [27, 28] . Conversely, KMT2D/MLL2, the most common recurrently mutated gene in human DLBCL (25-30% of cases), has been reported in $5% of canine DLBCL. However, other recurrently mutated human DLBCL genes (e.g., PIM1, MYD88) have not been reported in canine DLBCL. This could be because the number of canine exomes reported is not yet large enough to detect less frequent mutations in these genes, or because different genes are targeted for mutation in the two species.
Other '-omics' studies have also provided valuable comparative information. A database of all proteomic studies carried out in the dog in health and in disease, the CanisOme, was also developed with the goal of advancing animal health as well as the use of dogs as models for human disease [29 && ]. There have been three reviews published in the past year detailing all of the gene expression, cytogenetic, epigenetic, and proteomic canine studies completed to date to which the reader is referred for more in-depth information [30
NEW CANINE LYMPHOID CELL LINE RESOURCES
The availability of well characterized canine lymphoid cell lines facilitates the selection of appropriate in-vitro models for performing studies with clinical predictive value. Roode et al.
[33
&&
] characterized five canine leukemia/lymphoma cell lines with various methods and compared DNA copy number data from the cell lines with that from primary round cell tumors to determine if they represented the primary tumors and which subtype they most resembled. The Flint Animal Cancer Center assembled a panel of canine cancer cell lines with associated phenotypic and genotypic information as a resource for researchers in comparative oncology [34 && ]. There have also been two new canine lymphoid cell lines established from a B-cell leukemia [35] and natural killer T-cell lymphoma [36 & ], expanding the repertoire of cell lines available for study.
TREATMENT: USING DOGS FOR PRECLINICAL DATA IN HUMAN DRUG DEVELOPMENT
Targeted treatments such as therapeutic antibodies have become mainstream in treating human lymphoma due to their improved efficacy, and this has fostered great interest in expanding to other directed therapies to further improve patient survival. Here, we discuss how, as a proof of concept, spontaneous canine lymphoma has been used as a model in preclinical trials to test novel immunotherapies and other targeted drugs.
IMMUNOTHERAPY
The central rationale behind immunotherapy is that the immune system can be harnessed to recognize and eradicate neoplastic cells. Following the success of anti-CD20 therapeutic antibodies in treating diffuse large B-cell lymphoma in humans, numerous canine-specific anti-CD20 monoclonal antibodies are currently in development [40] . Blocking the immune checkpoint CD47/SIRPa together with anti-CD20 immunotherapy elicited an augmented response in xenograft mouse models bearing canine lymphoma [ . These preclinical in-vivo data enabled acalabrutinib to move into human trials [44] . Additional drugs triggering autophagy modulation [45] and procaspase-3 activation [46] have also been studied in pet dogs with spontaneous lymphoma, leading to their use in phase I clinical trials in humans.
CONCLUSION
Despite the recent advances in establishing the spontaneous canine lymphoma model, large knowledge gaps remain requiring the collaboration between different disciplines and sectors. The field of comparative oncology still needs additional clinical trial results, pathologic and genomic studies to better establish the areas of similarity between humans and dogs. Important human predictive/ prognostic factors (e.g., ABC/GCB, double expressor lymphoma, myc translocation) should be studied in the canine model to establish the relevance in this species. The value of performing preclinical trials in pet dogs will be better established with additional well powered clinical studies of novel therapeutic agents, including correlative studies to demonstrate similar biologic effects for targeted and immune therapies. Integrating pet dogs into the drug-development pipeline will ultimately enhance the predictability of treatment success and, in the long run, reduce the time and costs of therapeutic development. The author provides a detailed description of the molecular profiling and proteomic studies performed on canine blood and lymphoid tissue. 32.
